protocolSection identificationModule nctId: NCT06349642, orgStudyIdInfo id: MC230901, secondaryIdInfos id: 23-008413, type: OTHER, domain: Mayo Clinic Institutional Review Board, secondaryIdInfos id: NCI-2024-02979, type: REGISTRY, domain: CTRP (Clinical Trials Reporting Program), briefTitle: Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform, acronym: CYBRID-04, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-24, primaryCompletionDateStruct date: 2027-05, completionDateStruct date: 2027-05, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The primary purpose of this study is to determine the sensitivity of CYBRID Score for predicting in-vivo clinical response based on surgical response or RECIST 1.1 for neoadjuvant and locally advanced/metastatic patients, respectively. The secondary purposes is to determine the sensitivity of the CYBRID Score for predicting in-vivo clinical response based on surgical response or RECIST 1.1 for neoadjuvant and locally advanced/metastatic patients, respectively., conditionsModule conditions: Early Stage Triple-Negative Breast Carcinoma, conditions: Locally Advanced Bladder Urothelial Carcinoma, conditions: Locally Advanced Cervical Carcinoma, conditions: Locally Advanced Clear Cell Renal Cell Carcinoma, conditions: Locally Advanced Colorectal Carcinoma, conditions: Locally Advanced Endometrial Carcinoma, conditions: Locally Advanced Esophageal Carcinoma, conditions: Locally Advanced Liver Carcinoma, conditions: Locally Advanced Lung Non-Small Cell Carcinoma, conditions: Locally Advanced Malignant Skin Neoplasm, conditions: Locally Advanced Triple-Negative Breast Carcinoma, conditions: Metastatic Bladder Urothelial Carcinoma, conditions: Metastatic Cervical Carcinoma, conditions: Metastatic Clear Cell Renal Cell Carcinoma, conditions: Metastatic Colorectal Carcinoma, conditions: Metastatic Endometrial Carcinoma, conditions: Metastatic Esophageal Carcinoma, conditions: Metastatic Liver Carcinoma, conditions: Metastatic Lung Non-Small Cell Carcinoma, conditions: Metastatic Malignant Skin Neoplasm, conditions: Metastatic Malignant Solid Neoplasm, conditions: Metastatic Triple-Negative Breast Carcinoma, conditions: Resectable Bladder Urothelial Carcinoma, conditions: Resectable Colorectal Carcinoma, conditions: Resectable Lung Non-Small Cell Carcinoma, conditions: Resectable Malignant Liver Neoplasm, conditions: Resectable Skin Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 324, type: ESTIMATED, armsInterventionsModule interventions name: Biospecimen Collection, interventions name: Tissue Collection, outcomesModule primaryOutcomes measure: Accuracy of cytoplasmic hybrid (Cybrid) Score for predicting in-vivo clinical response, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Florida, status: RECRUITING, city: Jacksonville, state: Florida, zip: 32224, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Dev Mukhopadhyay, Ph.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.33218, lon: -81.65565, hasResults: False